Antisense Therapeutics Ltd (ANP)

Sydney
0.295
-0.020(-6.35%)
  • Volume:
    2,533,021
  • Bid/Ask:
    0.290/0.295
  • Day's Range:
    0.290 - 0.320

ANP Overview

Prev. Close
0.315
Day's Range
0.29-0.32
Revenue
-
Open
0.32
52 wk Range
0.091-0.35
EPS
-0.01
Volume
2,533,021
Market Cap
169.47M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
1,341,247
P/E Ratio
-
Beta
-0.48
1-Year Change
148%
Shares Outstanding
574,476,343
Next Earnings Date
-
What is your sentiment on Antisense Therapeutics Ltd?
or
Market is currently closed. Voting is open during market hours.

Antisense Therapeutics Ltd News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesSellSellSellBuyStrong Buy
Technical IndicatorsBuyStrong SellStrong SellStrong BuyStrong Buy
SummaryNeutralStrong SellStrong SellStrong BuyStrong Buy

Antisense Therapeutics Ltd Company Profile

Antisense Therapeutics Ltd Company Profile

Sector
Services
Employees
8
Market
Australia

Antisense Therapeutics Limited is an Australia-based biotechnology company. The Company is engaged in developing and commercializing antisense pharmaceuticals for unmet markets in rare diseases. The Company's product candidate, ATL1103, is an antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood. ATL1103 is in clinical development for acromegaly. The Company's product candidate, ATL1102, is an antisense inhibitor targeting very late antigen 4 (VLA-4), an immune cell molecule. The Company completed a Phase IIa efficacy and safety trial of ATL1102 in multiple sclerosis (MS) patients. The Company is engaged in clinical development of ATL1102 in patients with Duchenne Muscular Dystrophy (DMD). The Company is conducting a Phase II clinical trial of ATL1102 in DMD patients.

Read More
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.